search
Back to results

Advanced Directives in Palliative Care (DAVPAL) (DAVPAL)

Primary Purpose

End-of-life

Status
Completed
Phase
Not Applicable
Locations
Portugal
Study Type
Interventional
Intervention
Advance Directives
Control
Sponsored by
Universidade do Porto
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for End-of-life focused on measuring palliative care, Advance Directives, caregivers, End-of-life decision-making

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patients with 18 years or more
  • Patients referenced to the palliative care service with a chronic, progressive, and incurable disease
  • Patients with the ability to comprehend, write and speak the Portuguese language
  • Patients with an absence of major cognitive disorders (Portuguese validated Mini-Mental State Test score superior to 22, 25, or 27, according to patients' scholarly)
  • Patients that accepted to participate in the trial
  • Patients who were capable of nominate a caregiver as their surrogate in decision making
  • Adult caregivers with 18 years or more
  • Caregivers who were nominated by patients as their surrogate decision-maker
  • Caregivers with the ability to comprehend, write and speak the Portuguese language
  • Caregivers that accepted to participate in the trial

Exclusion Criteria:

  • Patients or caregivers that refused to participate
  • Patients with cognitive impairment
  • Patients with incapacity to dialogue
  • Patients who were too sick to cooperate
  • Patients without a caregiver

Sites / Locations

  • Tràs-os-Montes and Alto Douro Hospital Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

- Advance Directives Group

Control Group

Arm Description

The group that will receive the principal physician intervention, using Advance Directives document as a communication tool between patients and caregivers, to find its efficacy on the promotion of better-prepared surrogates

The group that will receive the Placebo Intervention, consisting of a clinical evaluation of patients' clinical status, by the physician

Outcomes

Primary Outcome Measures

Agreement between patients´ and caregivers´ answers in the Advance Directives´ document
Agreement between patients and their caregivers was accessed with the Overall Proportion of Agreement (Overall PA) and Proportion of Specific Agreement (Yes PA and No PA), for the 12 questions of the Portuguese Advance Directives, on the Advance Directives and Control group
Reliability of the results of agreement between patients´ and caregivers' answers in the Advance Directives´ document
Reliability was accessed with Cohen's kappa (k). (Cohen, 1960). We assumed Landis and Koch's (1977) interpretation of κ value. According to these authors, a κ value of 0.20 represents slight reliability, a value between 0.21 and 0.40 fair reliability, a value between 0.41 and 0.60 moderate reliability, a value between 0.61 and 0.80 substantial reliability, and a value of 0.81-1.00 indicates almost perfect reliability

Secondary Outcome Measures

Agreement between caregivers' answers as patients' surrogates and caregivers' answers about their own end-of-life preferences
Agreement between caregivers as surrogates and their own preferences was accessed with the Overall Proportion of Agreement (Overall PA) and Proportion of Specific Agreement (Yes PA and No PA), for the 12 questions of the Portuguese Advance Directives, on the Advance Directives and Control group

Full Information

First Posted
September 28, 2021
Last Updated
March 2, 2022
Sponsor
Universidade do Porto
search

1. Study Identification

Unique Protocol Identification Number
NCT05090072
Brief Title
Advanced Directives in Palliative Care (DAVPAL)
Acronym
DAVPAL
Official Title
Advanced Directives in Palliative Care: Physician's Role on Caregiver's Empowerment as Patient's Surrogates
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
September 10, 2018 (Actual)
Primary Completion Date
August 23, 2019 (Actual)
Study Completion Date
April 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidade do Porto

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A prospective, single-blinded, controlled, and randomized trial to find if physician's use of the Portuguese Advance Directives, in palliative care, as a communication tool between patients and caregivers, improves the agreement and reliability between patients and their health surrogates, in their decisions about end-of-life care.
Detailed Description
This trial was a prospective, single-blinded, controlled, and randomized study analyzing if Advance Directives' discussion between patients and caregivers, promoted by a palliative care physician, improves concordance between them, concerning to patients' last wishes, therefore improving surrogates' accuracy when caregivers decide and act on behalf of the patients. This trial was conducted in a central hospital of Portugal's north inland, serving an estimated population of 465.000 habitants. Patients referenced to all three units of the palliative care service from September 2018 to September 2019, and caregivers, were sequentially approached and recruited on the first consult. All participants gave written consent to enroll in the trial. This study occurred in two phases, within a 1-month interval. At baseline (phase 1) participants separately fulfilled the Advance Directives' document considering patients' preferences for end-of-life care. Caregivers also fulfill a similar document with their own end-of-life preferences. Dyads were then randomly assigned to two different groups - The Advance Directives and the Control groups. Simple individual randomization was previously informatically achieved and the randomization sequence was disclosed by a sealed envelope only after trial enrollment of the dyad, to ensure proper investigator concealment. Both patients and caregivers were blinded to the assigned group until the end of the trial. In both groups (Advance Directives and Control), dyads were engaged in a conference meeting, in the same room, with the same average duration, with the same investigator. In the Advance Directives group, the palliative care physician promoted an open discussion between patients and caregivers, about patients' answers to the Advance Directives document. In the Control group, the palliative care physician underwent a conference with both patients and caregivers to evaluate patients' clinical symptoms. At phase 2, one month after the first interview, caregivers were asked to fill in another Advance Directives document, as patients´ surrogates. Each participant had the choice to drop out at any moment of the trial, and the pair was excluded from data analysis. Portuguese official Advance Directives was the central instrument used in this trial. Participants were asked to choose 1 to 3 different scenarios, to apply the following 12 questions regarding end-of-life preferences. Each question in each scenario was informatically registered as a Yes or No item, respectively corresponding to items selected or not by all participants. For each participant, the investigators expected 36 possible answers for concordance analysis. Categorical variables were described by absolute and relative frequencies. Age was described by the mean and standard deviation (mean ± SD), as its distribution was not deviated from normality in each group, according to visual analysis of histograms and confirmed with the Shapiro-Wilk's test of normality. Agreement between patients and caregivers was assessed (in each question) with the Overall Proportions of Agreement (Overall PA) and Proportions of Specific Agreement (for Yes and No), with respective 95% confidence intervals. Reliability was accessed with Cohen's kappa (k). Descriptive data analysis was performed using SPSS® Statistics. Proportions of agreement and Cohen's κ with respective confidence intervals were computed using packages "obs. agree" and "psych" from R software, v 3.4.0.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End-of-life
Keywords
palliative care, Advance Directives, caregivers, End-of-life decision-making

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
After enrollment and some sociodemographic data were collected, participants were asked to, separately, fulfill the Advance Directives document, concerning patients' last wishes. Caregivers also fulfill one document with their own end-of-life preferences. The pair was then randomly assigned to one of the two parallel groups (Advance Directives or Control Group). Both groups had a conference meeting with the same palliative care physician, in the same room, with the same average duration (40 to 50 minutes). The Advance Directives Group discussed patients' answers to the Advance Directive document, and the Control Group talked about patients' clinical status. Two months later, caregivers only, were asked to fulfill another Advance Directive document as patients' surrogates.
Masking
Participant
Masking Description
All participants were blinded to the allocated intervention, from the beginning to the end of the trial. Investigator only had access to the allocation group after participants enrollment on the trial, sociodemographic data collected, and phase 1 Advance Directives fulfilled. Preliminary data analysis was made without knowledge of the participants' allocated group
Allocation
Randomized
Enrollment
116 (Actual)

8. Arms, Groups, and Interventions

Arm Title
- Advance Directives Group
Arm Type
Active Comparator
Arm Description
The group that will receive the principal physician intervention, using Advance Directives document as a communication tool between patients and caregivers, to find its efficacy on the promotion of better-prepared surrogates
Arm Title
Control Group
Arm Type
Placebo Comparator
Arm Description
The group that will receive the Placebo Intervention, consisting of a clinical evaluation of patients' clinical status, by the physician
Intervention Type
Behavioral
Intervention Name(s)
Advance Directives
Intervention Description
The palliative care physician engaged patients and their caregivers in an open discussion about patients' answers to the Advance Directives document, to explore and clarify all doubts and questions prompted by the document
Intervention Type
Behavioral
Intervention Name(s)
Control
Intervention Description
The palliative care physician undergone a conference with both patients and caregivers and evaluated patients' symptoms using the the Edmonton Frail Scale (Bruera, 1991), adapted to the Portuguese population. The Advance Directives theme wasn't approached during this conference.
Primary Outcome Measure Information:
Title
Agreement between patients´ and caregivers´ answers in the Advance Directives´ document
Description
Agreement between patients and their caregivers was accessed with the Overall Proportion of Agreement (Overall PA) and Proportion of Specific Agreement (Yes PA and No PA), for the 12 questions of the Portuguese Advance Directives, on the Advance Directives and Control group
Time Frame
1 month
Title
Reliability of the results of agreement between patients´ and caregivers' answers in the Advance Directives´ document
Description
Reliability was accessed with Cohen's kappa (k). (Cohen, 1960). We assumed Landis and Koch's (1977) interpretation of κ value. According to these authors, a κ value of 0.20 represents slight reliability, a value between 0.21 and 0.40 fair reliability, a value between 0.41 and 0.60 moderate reliability, a value between 0.61 and 0.80 substantial reliability, and a value of 0.81-1.00 indicates almost perfect reliability
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Agreement between caregivers' answers as patients' surrogates and caregivers' answers about their own end-of-life preferences
Description
Agreement between caregivers as surrogates and their own preferences was accessed with the Overall Proportion of Agreement (Overall PA) and Proportion of Specific Agreement (Yes PA and No PA), for the 12 questions of the Portuguese Advance Directives, on the Advance Directives and Control group
Time Frame
1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients with 18 years or more Patients referenced to the palliative care service with a chronic, progressive, and incurable disease Patients with the ability to comprehend, write and speak the Portuguese language Patients with an absence of major cognitive disorders (Portuguese validated Mini-Mental State Test score superior to 22, 25, or 27, according to patients' scholarly) Patients that accepted to participate in the trial Patients who were capable of nominate a caregiver as their surrogate in decision making Adult caregivers with 18 years or more Caregivers who were nominated by patients as their surrogate decision-maker Caregivers with the ability to comprehend, write and speak the Portuguese language Caregivers that accepted to participate in the trial Exclusion Criteria: Patients or caregivers that refused to participate Patients with cognitive impairment Patients with incapacity to dialogue Patients who were too sick to cooperate Patients without a caregiver
Facility Information:
Facility Name
Tràs-os-Montes and Alto Douro Hospital Centre
City
Vila Real
ZIP/Postal Code
5000-508
Country
Portugal

12. IPD Sharing Statement

Citations:
PubMed Identifier
35820845
Citation
Martins CS, Sousa I, Barros C, Pires A, Castro L, da Costa Santos C, Nunes R. Do surrogates predict patient preferences more accurately after a physician-led discussion about advance directives? A randomized controlled trial. BMC Palliat Care. 2022 Jul 12;21(1):122. doi: 10.1186/s12904-022-01013-3.
Results Reference
derived

Learn more about this trial

Advanced Directives in Palliative Care (DAVPAL)

We'll reach out to this number within 24 hrs